ASH 2018 | Treatment facility volume-outcome relationship exists in Waldenström’s
Waldenström’s Macroglobulinemia (WM) is a rare disease; therefore, a general hematologist-oncologist’s experience of the management of WM is likely to be limited. Here, Jonas Paludo, MD, of the Mayo Clinic, Rochester, MN, discusses the relationship between treatment facility volume and outcomes in WM, from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. This revealed that patients treated initially at higher volume facilities had a lower risk of mortality.
Get great new content delivered to your inboxSign up